Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated